Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

1 Aug Investec 313.00 Hold

A buy in this weeks IC - Burton-on-Trent based specialist medicines supplier Clinigen (CLIN) looks to be performing well after the company reported that it looks on course to beat forecasts for earnings this year. Clinigen reports its full year results on Wednesday 25 Sept 2013. The run should continue with the first substantial contributions from acquired products.

Up 10.36% - Clinigen Group PLC (CLIN:LSE) set a new high during today's trading session when it reached 396.75. Since the IPO on Sep 25, 2012, the share price is up 125.43%.

A buy in this weeks shares mag - House broker Numis reckons Clinigen can spend £40m on acquisitions over the next year. The shares deserve their high rating - trading on 19.4 times forecast earnings for 2013 - because of growth momentum, management expertise and market opportunities.

Notice of Results

RNS


RNS Number : 3324N

Clinigen Group plc

06 September 2013






Clinigen Group plc

Notification of Full Year Results Date

Burton-on-Trent, UK - 6 September 2013 - Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its full year results for the period ended 30 June 2013 on Wednesday, 25 September 2013.

A group analyst briefing will be held at 09:30am GMT on Wednesday, 25 September 2013 at the Group's London offices at 1 King Street, London EC2V 8AU. Analysts who wish to participate should either contact Claire Dickinson on +44 (0)20 7457 2020 or email Clinigen@CollegeHill.com to register.

- Ends -

Clinigen Group PLC




Clinigen Group plc is a fast-growing specialty global pharmaceuticals and services business, dedicated to serving patients, the medical community and the healthcare industry to supply critical life saving treatment. With offices in the UK, US and Japan, Clinigen is focused on delivering the right drug to the right patient at the right...



Clinigen seals epilepsy drug deal with Eisai
By Jamie Nimmo September 09 2013, 7:38am Epilepsy is a common neurological condition that causes seizuresEpilepsy is a common neurological condition that causes seizures

AIM-listed pharma company Clinigen (LON:CLIN) has unveiled a deal with Eisai that will see it manage an access programme for its anti-epilepsy drug Fycompa in Germany.

The agreement will mean an uninterrupted supply of the drug at no cost to the German healthcare system following the temporary suspension of commercial distribution in the country.

The programme will be managed by Clinigen GAP (Clinigen Global Access Programs) and will begin when stocks of the drug run out in Germany, which is not expected to happen until the end of this calendar year.

Fycompa is the only drug approved in Europe for countering the effects of epilepsy, a common neurological condition that causes seizures.

Chief executive Peter George said: “We look forward to assisting in the provision of continued access to Fycompa in Germany and are pleased with the confidence entrusted in us by Eisai.

“As a specialist provider of global access programmes we have the experience and expertise to deliver this bespoke access programme within Germany.”

He added: “This programme represents the addition of another major pharmaceutical company to our expanding client base.”

In Shares this week - Clinigen is in good health, better than expected results on the way a year after aim listing.

On the year to the day it joined Aim (25 Sept) the group will report sales and growth profits that could well exceed expectations, owing to robust organic growth and lower than expected costs. The market is looking for sales of £120.6 m and £20.8m pre-tax profit, double that achieved last year. It will also declare its maiden dividend of 1.8p per share, equivalent to a 0.5% yield.

European Marketing Authorisation transfer on track
RNS
RNS Number : 0396O
Clinigen Group plc
16 September 2013





Clinigen Group on Track with European Marketing Authorization Transfers for Cardioxane® and VIBATIV®

Burton-on-Trent, UK - 16 September 2013 - Following the acquisition of Cardioxane® from Novartis and the in-licensing of VIBATIV® from Theravance, Inc. in March 2013, Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN) today reported significant progress in the handover of these products with the transfer of key Marketing Authorizations in Europe to Clinigen. The transfers have progressed according to internally agreed timelines and both projects are continuing on schedule.

For oncology support therapy Cardioxane® (dexrazoxane), Marketing Authorizations in France, the UK, the Netherlands, and Poland have been transferred from Novartis to Clinigen. As Marketing Authorization holder Clinigen has assumed responsibility for manufacturing, registration, distribution, and commercialization of Cardioxane® in these countries, ensuring a smooth transition and an uninterrupted supply of the drug to patients. Clinigen plans to transfer all Marketing Authorizations from Novartis and fully manage supply globally by the end of 2014, which is a similar timeline to Foscavir® when it transferred from AstraZeneca to Clinigen.

Furthermore, the European Commission has approved the transfer of Marketing Authorization for the anti-bacterial VIBATIV® (telavancin) from Theravance, Inc. to Clinigen. VIBATIV® has been suspended for use in the European Union since 2012 following a suspension of operations at the contract manufacturer. Having completed the technical transfer to a new contract manufacturer, Clinigen is working closely with the European Medicines Agency to remove the marketing suspension and expects to have European product available, as planned, in the first quarter of 2014.

For countries where Cardioxane® and VIBATIV® do not have Marketing Authorization, Clinigen will leverage the capabilities of its Global Access Programs business (Clinigen GAP) to supply the medicines on a named patient basis.

"The transfer of the European Marketing Authorizations to Clinigen marks an important step in the integration of both Cardioxane® and VIBATIV® into our Specialty Pharmaceuticals business," said Peter George, Chief Executive Officer, Clinigen Group. "Clinigen has now assumed full control of all key commercialization activities and will provide further updates as we begin to realize the benefit of supplying Cardioxane® directly. In addition, our priority for the remainder of the year is to work towards lifting the current suspension of the Marketing Authorization for VIBATIV®."



- Ends -

Sun, 22 September 2013


Since floating on AIM almost a year ago, Clinigen has done just what it said it would, Matthew Goodman wrote in the Sunday Times. The pharmaceutical company has produced new drugs, such as a breast cancer treatment, and has boosted its income. The shares have been rewarded by more than doubling in price since being traded. Management’s lock-up period ends soon but if they decide to cash in this may be offset by pent-up demand, Goodman said.


http://sharecast.com/news/share-tips-foxtons-unite-ag-barr/21172803.html

Nice write up in The Sunday Times.

Final Result
25 Sep 13 Clinigen Group [CLIN]

Preliminary Results

RNS


RNS Number : 8086O

Clinigen Group plc

25 September 2013












Clinigen Group plc

Preliminary Results for the year ended 30 June 2013

Burton-on-Trent, UK - 25 September 2013 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2013.

Financial highlights

- Group revenue up by 49% to £122.6m (FY12: £82.1m) driven by strong organic growth across all three operational businesses

o Clinigen CTS full year sales up 49% to £87.8m and full year gross profit up 13% to £11.4m

o Clinigen GAP revenue grew more than six-fold to £10.5m; full year gross profit was up more than five-fold to £3.9m

o Clinigen SP full year sales of £24.3m (+12%) and full year gross profit of £19.8m (+8%)

- Underlying EBITDA increased by 30% to £22.4m (FY12: £17.3m)

- Underlying pre-tax profit increased by 29% to £20.4m (FY12: £15.8m) and reported pre-tax profits increased by 42% to £14.5m (FY12: £10.3m)

- Underlying earnings per share up 38% to 18.5 pence (FY12: 13.4 pence) and reported earnings per share 15.1 pence (FY12: 13.2 pence)

- Cash generation continues to be strong; cash and cash equivalents at 30 June 2013 were £11.3m, up from £5.2m at 30 June 2012

- Final dividend of 2.0 pence per share proposed, bringing the total dividend to 2.6 pence per share



Business highlights

- Clinical Trial Supply ("CTS")

o Sales performance driven by sizable anti-viral studies and increased activity in the US

o In June, extension of exclusive EU supply agreement with Accord Healthcare

- Global Access Programs ("GAP")

o Awarded Sanofi's Campath and Astellas' MDV3100 early access programs

o In July, BTG awarded a third access program to Clinigen and, in September, Eisai selected Clinigen to manage an access program in Germany

- Specialty Pharmaceuticals ("SP")

o Foscavir® sales volume continued to grow, with further expansion into the US and new indications in Europe

o Exclusive commercialization agreement in EU for Antibacterial, VIBATIV®

o Acquisition of oncology support therapy, Cardioxane® for US$33m





Peter George, Chief Executive Officer, said:



"We have over-delivered on our commitments made at the time of the IPO last September. In turn, the listing on AIM has lived up to our expectations. It has provided a stronger platform from which to drive our organic growth, both in the UK and internationally, as well as giving us additional financial flexibility to support our acquisition plans and the acceleration of our international growth strategy. The IPO has also enabled greater investment in the infrastructure and recruitment of additional high quality people to the business.



"Our ambition for the next financial year is to maintain this momentum across all three operating businesses; principally organic growth for CTS and GAP, and through further acquisition of products for SP. Geographically, we are focusing our attention on the US, Latin America and Asia.



"With a sound financial base, an increasing international footprint, as well as the recent organizational changes, we have the right foundations to continue the scale-up of the business and maintain our growth."



-Ends-

Clinigen: Investec places both its target price (prev.: 313p) and its hold recommendation unchanged


25 Sep Numis 485.00 Buy

City analysts hail Clinigen results
By Giles Gwinnett September 25 2013, 11:31am All three of the firm's divisions - Clinical Trial Supply (CTS), Global Access Programs (GAP) and Specialty Pharmaceuticals (SP) - saw an increase in sales or revenue.All three of the firm's divisions - Clinical Trial Supply (CTS), Global Access Programs (GAP) and Specialty Pharmaceuticals (SP) - saw an increase in sales or revenue.

---ADDS BROKER COMMENT AND SHARE PRICE---

Global pharma and services business Clinigen (LON:CLIN) posted full year results on Wednesday that beat analysts' forecasts.

The group unveiled a 49% increase in group revenues, driven by strong growth across all three of its operations.

In the year to end June, revenue stood at £122.6mln compared to £82.1 mln in 2012, while underlying pre-tax profit was up 29% to £20.4mln compared to £15.8mln last year.

Investors welcomed the numbers and Clinigen shares zoomed further upwards - 6.7% to 430p. The shares are now at an all time high and have doubled since the beginning of 2013.

The firm also ended the year in a good cash position, having £11.3mln - more than double the £5.2mln it had at June 20, 2012, and declared a final divi of 2p a share, making the total dividend for the year 2.6p a share.

All three of the firm's divisions - Clinical Trial Supply (CTS), Global Access Programs (GAP) and Specialty Pharmaceuticals (SP) - saw an increase in sales or revenue.

CTS, the largest contributor to sales, saw sales rise 49% to £87.8mln. This arm sources and supplies comparator drugs for use by big pharma and large research organisations when they are carrying out clinical trials.

GAP, whose revenue grew more than six-fold to £10.5mln, provides drugs that are still in trials but showing signs of efficacy.

SP, as the name suggests, is focused on acquiring medicines, developing and registering them before onward marketing. In the year, it saw sales increase 12%.

Broker Numis, which rates the shares a 'buy' targeting 485p, highlighted the firm's stated ambition to become the market leader in both CTS and GAP through organic growth, and to add a further 5-7 speciality pharmaceutical (SP) products over the next three to five years.

"If it accomplished this, we see over 100% upside to our 5-year earnings forecasts," says analyst Charles Weston.

As well as revenue and EBITDA beating forecasts, the broker said the full year dividend of 2.6p was considerably better than its 1.8p estimate, and net cash was £4mln better than expected, at £11mln.

Meanwhile, Investec said: "Clinigen’s preliminary results have come in ahead of our, and consensus, expectations in spite of 10% upgrades only two months ago."

The broker notes that although the share price has risen sharply in recent months, it believes the current ratings are "not a stretch given these results".

"We place our price target and recommendation under review,” it adds.

Earlier, the group's chief executive Peter George told investors: "We have over-delivered on our commitments made at the time of the IPO last September.

"In turn, the listing on AIM has lived up to our expectations. It has provided a stronger platform from which to drive our organic growth, both in the UK and internationally, as well as giving us additional financial flexibility to support our acquisition plans and the acceleration of our international growth strategy.

"The IPO has also enabled greater investment in the infrastructure and recruitment of additional high quality people to the business.

“Our ambition for the next financial year is to maintain this momentum across all three operating businesses; principally organic growth for CTS and GAP, and through further acquisition of products for SP. Geographically, we are focusing our attention on the US, Latin America and Asia.

“With a sound financial base, an increasing international footprint, as well as the recent organisational changes, we have the right foundations to continue the scale-up of the business and maintain our growth.”

Clinigen says momentum has carried into the new financial year
By Jeremy Naylor September 25 2013, 1:03pm

Well worth a watch.

http://www.proactiveinvestors.co.uk/companies/stocktube/2204/clinigen-says-momentum-has-carried-into-the-new-financial-year-2204.html

Thanks dreamcatcher

Pleased I can help

A buy in this weeks IC - Clinigen just the medicine.

Clinigen's share price has doubled since Jan 13 but rated on 16 times June 2015 earnings estimates, there should be more to come.

Clinigen directors to sell shares via placing
By Jamie Ashcroft September 30 2013, 5:16pm Books open on the placing right away and the pricing will be announced ‘as soon as practicable’ once the books close.Books open on the placing right away and the pricing will be announced ‘as soon as practicable’ once the books close.

Specialty pharmaceuticals firm Clinigen (LON:CLIN) announced on the AIM close that 10.6% of the group’s shares will be sold via a share placing.

Through the placing, which is being run by Numis and Peel Hunt, just over 8.7mln shares will be sold by the company’s directors.

Books open on the placing right away and the pricing will be announced ‘as soon as practicable’ once the books close.

It is planned that chief executive Peter George will sell just over 30% of his stake in the company, leaving him with a 7.3% shareholding (6mln shares).

Chief financial officer Robin Sibson and chief operating officer Shaun Chilton are also named as selling directors – each halving their stakes leaving them with 3% and 0.4% respectively.

Other un-named employees are also participating and those sales will account for around 3mln of the placing shares.

Last week Clinigen posted full year results that beat analyst forecasts.

It unveiled a 49% increase in group revenues, driven by strong growth across all three of its operations.

In the year to end June, revenue stood at £122.6mln compared to £82.1 mln in 2012, while underlying pre-tax profit was up 29% to £20.4mln compared to £15.8mln last year.